Post-marketing research in oncology has rarely been described. We aimed to characterize post-marketing trials for a consistent set of anticancer agents over a long period. We performed a cross-sectional analysis of post-marketing trials registered at ClinicalTrials.gov through September 2014 for novel anticancer agents approved by both the US Food and Drug Administration and the European Medicines Agency between 2005 and 2010. All relevant post-marketing trials were classified according to indication, primary outcome, starting date, sponsors, and planned enrollment. Supplemental indications were retrieved from regulatory documents and publication rate was assessed by two different methods. Ten novel anticancer agents were eligible: five were indicated for hematologic malignancies and the remaining five for solid cancers (three for kidney cancer). We identified 2,345 post-marketing trials; 1,362 (58.1%) targeted an indication other than the originally approved one. We observed extreme variations among drugs in both number of post-marketing trials (range 8-530) and overall population to be enrolled per trial (1-8,381 ). Post-marketing trials assessed almost all types of cancers, the three most frequently studied cancers being leukemia, kidney cancer and myeloma. In all, 6.6% of post-marketing trials had a clinical endpoint as a primary outcome, and 35.9% and 54.1% had a safety or surrogate endpoint, respectively, as a primary outcome. Nine drugs obtained approval for supplemental indications. The publication rate at 10 years was 12.3 to 26.1% depending on the analysis method. In conclusion, we found that post-marketing research in oncology is highly heterogeneous and the publication rate of launched trials is low.
Clinical research preceding marketing authorization is highly regulated [1] [2] [3] and has been extensively studied. [4] [5] [6] [7] [8] [9] [10] Although this is an evolving field 11, 12 and despite some differences among regulators, preapproval trials are well known and codified. However, once a drug has been approved for use, subsequent clinical trials are much less regulated 13 and have not been thoroughly characterized. Indeed, drug manufacturers, academics or any organization are loosely constrained in the design and conduct of post-marketing trials. The temptation to test authorized drugs in other conditions seems particularly substantial, particularly in oncology. Indeed, cancers often share some growth mechanisms and in agreement, drugs share a certain degree of efficacy among several types of tumors, 14 thereby fostering scientific interest to test already approved drugs in other indications. For instance, imatinib, the first so-called targeted therapy was initially approved for adult patients with Philadelphia positive chronic myeloid leukemia. However, it was subsequently found effective for other hematologic or solid neoplasms and its US label now lists up to 10 indications. 15 We aimed to analyze post-marketing trials for all novel anticancer agents approved by both the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) between 2005 and 2010. In particular, we sought to quantitatively assess testing after approval, to study population characteristics, alignment with the primary label or novel testing in other cancers, and selected primary outcomes. We also evaluated approvals of supplemental indications for the drugs and publication of results of launched post-marketing trials.
Material and Methods

Data sources and study sample
From prior work, we identified all novel drugs approved by both the FDA and EMA between January 1, 2005 and December 31, 2010 (Zeitoun, 2017, submitted). We excluded generic drugs, reformulations, combination therapies and non-therapeutic agents such as radiographic dye. The end of the approval period was defined as 2010 to allow a minimum of nearly 4 years of post-approval follow-up. Then, for the current study, anticancer agents were selected after manual review of the initial label.
Drug characteristics
The following data were retrieved for all anticancer agents included in our sample: agent type (small molecule or biologic), dates of regulatory submissions for both the FDA and EMA, orphan status according to the FDA, orphan designation from the EMA, initial label, and degree of novelty (first-in-class, advance-in-class, addition-to-class) as previously described. 16 Manufacturers were classified as large pharmaceutical companies, intermediated-size companies or small-and medium-sized companies, according to the European Union definition, based on headcount and financials turnover or balance sheet total. We retrieved data from pivotal efficacy trials supporting approval data that had been collected in previous work, 5 namely the type of comparator, trial endpoint and cumulative number of patients included in preapproval trials. Those data had been extracted and structured from FDA medical reviews included in Drugs@FDA, a publicly accessible database that lists regulatory actions of the agency. For each drug, pivotal efficacy trials, labeled as such by the FDA, were identified and analyzed in terms of the type of comparator (active, placebo, none), primary endpoint (clinical, surrogate), and number of recruited patients.
Post-marketing trials
On September 24, 2014, we exported all trials registered at ClinicalTrials.gov, a publicly accessible clinical trial registry maintained by the US National Institutes of Health, for each drug of our sample, regardless of dates and other details. We then excluded trials with the following characteristics: included in the FDA regulatory submission (through manual review of Drugs@FDA, a publicly accessible database listing relevant regulatory actions for all approved drugs); with registered status unfit for the current research (expanded access trials, withdrawn trials, suspended trials); mistakenly extracted; and with a start date at least 1 year or earlier before the first regulatory submission (to the FDA or EMA). Finally, we manually reviewed trials related to more than one drug of the sample so as to assign only one drug to each trial for further statistical analysis. Clinical judgment was applied to choose the "leading drug" for each trial (detailed information is in the Supporting Information Material).
For all remaining post-marketing trials, the following data were collected and structured: condition studied (according to the categorization of reference from the Global Burden of Disease), 17 starting date, study sponsors (as a main sponsor or a collaborator), status at the date of extraction (not yet recruiting, recruiting, active yet not recruiting, enrolling by invitation, completed, terminated), number and list of countries, number What's new? In contrast to clinical research preceding drug approval, post-marketing research is much less regulated and has rarely been described. This study characterized nearly 10 years of post-marketing research for all novel anticancer agents approved by the Food and Drug Administration and European Medicines Agency between 2005 and 2010. There was a high degree of heterogeneity in the number of trials and size of population to be enrolled. 60% of post-marketing trials were designed for a new indication, most commonly hematologic and kidney cancers. Very few trials had a clinical endpoint as a primary outcome, and publication rate was particularly low.
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of centers, trial phase, study type (observational or interventional), randomization, and planned enrollment. In addition, all trials were manually reviewed to classify each as targeting the originally approved indication or not, depending on the label. When the initial label differed between the FDA and EMA, we accepted both as defining the originally approved indication. One of us (JDZ) performed this classification after full manual review of each initial label. All related details are provided as Additional Supporting Information.
Finally, we sought to classify the primary outcome of each post-marketing trial as follows: clinical endpoint, surrogate endpoint, safety, pharmacologic, and other. Post-marketing trials measuring overall survival, time to death or any quality-of-life indicator as a primary outcome were considered to have a clinical endpoint. The following primary outcomes were considered surrogate: response rate, pathologic complete response, disease-free survival, progression-free survival, time to disease progression, any measure of a biomarker, molecular response or imaging monitoring, or minimal residual disease (for hematologic malignancies). The following measures were considered safety endpoints: tolerability, toxicity, safety, adverse effects, maximum tolerated dose, dose-limiting toxicity, or any attempt to understand or study a specific and already known adverse effect of the drug. We considered pharmacologic trials as having the following primary outcomes: pharmacokinetics, pharmacodynamics, bioavailability or area under the curve.
Supplemental indications
Approvals of supplemental indications by the FDA during the study period (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) were collected from Drugs@FDA, specifically at the "Approval Date(s) and History, Letters, Labels, Reviews" section. All events designated as "efficacy-new indication" or "efficacy" were reviewed and included if appropriate. Labeling revisions and manufacturing change or addition were not considered, nor were non-relevant supplemental indications.
Publications
For each post-marketing trial, publication status was determined by two approaches. First, we cross-checked data extracted from ClinicalTrials.gov and from MEDLINE. Investigators of a given trial should post on ClinicalTrial.gov the reference of related scientific articles when published. Therefore, for each trial of our sample, we screened links referred to as "Reference Results" to identify a sample of published articles related to the clinical trial. Reciprocally and in parallel, we used the "E-utilities" functionality on MEDLINE that allows for determining whether a given trial identified by its ClinicalTrials.gov identifier (i.e., NCT) is recorded on MED-LINE at the date of the search. Adding the resulting samples of published articles and removing overlapping references led to a first assessment of publications from our post-marketing trials. Second, we used a novel tool created for a not-forprofit purpose (https://trialstracker.ebmdatalab.net/#/) to track publications of trials registered at ClinicalTrials.gov. This method is fully disclosed on the website and use of the tool is free for any researcher. For both methods, we further excluded articles that had been published <18 months after the trial start date, assuming that they would be spurious publications, unrelated to the trial.
Statistical analysis
We used descriptive statistics to characterize novel drugs included in our sample and to characterize features of postmarketing trials registered at ClinicalTrials.gov for all novel drugs of the study sample. We used the Kaplan-Meier method to estimate the cumulative publication rate for postmarketing trials over time. The Log rank test was used to compare the distribution of post-marketing trials by the main sponsor (industry vs. other). We used SAS 9.4 (SAS Institute; Cary, NC) for all statistical analyses.
Results
Study sample
Between January 1, 2005 and December 31, 2010, 13 novel medicines were approved by both the FDA and EMA for oncologic indications: dasatinib, denosumab, everolimus, lapatinib, lenalidomide, nelarabine, nilotinib, ofatumumab, panitumumab, pazopanib, sorafenib, sunitinib, temsirolimus (alphabetical order). Denosumab was approved for treating bone loss associated with hormone ablation in men with prostate cancer and was not specifically considered an anticancer agent. Data extracted from ClinicalTrials.gov regarding everolimus and temsirolimus were spurious because most trials were related to drug-eluting coronary stents, and therefore the two drugs were excluded from subsequent analyses. The final study sample was 10 novel anticancer agents approved by both the FDA and EMA between 2005 and 2010. These 10 novel drugs were approved for 13 indications: seven (70%) for a single indication and three (30%) for 2 indications. Five drugs were approved for hematologic malignancies and the remaining five for solid cancers (three for kidney cancer). Other characteristics regarding the 10 novel anticancer agents are in Tables 1 and 2 .
Post-marketing trials and populations
A total of 2,345 post-marketing trials were recorded for all 10 anticancer agents of our study sample, with significant differences in number of trials among drugs (Table 2 and Fig.  1 ). The median number of post-marketing trials per drug was 187 [interquartile range (IQR) 118-358] with a minimum of 8 (nelarabine) and a maximum of 531 (sorafenib).
Data regarding the overall population to be included in all post-marketing trials and the respective share of industry and non-industry funders are in displayed as Supporting Information Figure S1 . The median cumulative population per anticancer agent was 20,959 (IQR 15,657-45,881) and the median sample size per trial was 47 (IQR 25-100; range 1 to 8,381 patients to be enrolled). The median sample size at the drug level ranged from 40 (lapatinib) to 64 (panitumab). The ranking by number of post-marketing trials was not rigorously aligned in terms of population size (Fig. 1) . However, sorafenib and lenalidomide were both associated with the greatest number of post-marketing trials and the highest population to be recruited. In contrast, nelarabine and ofatumumab both had the lowest number of post-marketing trials and the smallest population to be enrolled. Supporting Information Figure S2 compares population sizes for preapproval and post-marketing trials, showing moderate correlation (Spearman correlation coefficient 5 0.54).
Targeted indications
Among all post-marketing trials, 1,362 (58.1%) were considered to target another cancer than the one for which it was initially approved. Here again, we found great variation among drugs in post-marketing testing (see Table 2 ), with nelarabine, lapatinib and nilotinib rarely assessed for cancers other than the one for which they were initially approved, and others, such as pazopanib and sorafenib, intensively tested in other cancers.
Some post-marketing trials recruited patients with several types of cancers and others were designed for non-oncologic indications. Almost all existing cancers were studied, yet the three most frequently recorded cancers were leukemia (acute or chronic), kidney and other urinary organ cancers, and multiple myeloma, representing 35.4% of all previously mentioned indications. Other data related to the types of cancers studied are in Figure 2 and in also in the Supporting Information FigureS3.
After approval, novel anticancer agents were subsequently tested in a mean of 16.9 types of cancer (SD 8.6), ranging from 2 (nelarabine) to 26 (sorafenib) types. In all, 202 postmarketing trials (7.7%) recruited patients with rare cancers (consisting of residual causes from major cancer groups), and 162 (6.2%) recruited patients with more than three types of cancer (i.e., trials that considered multiple cancer types), mostly any cancer in some kind of undifferentiated phase II trial. Other aggregated data regarding post-marketing trials are in Supporting Information Table S1 .
Outcomes
Figure 3 presents our findings regarding the accumulation of post-marketing trials for each drug over time, with their primary outcome (by the pattern of each point) and the alignment of the targeted cancer with the original indication (by the color of each point). After excluding irrelevant trials, we found 2,331 post-marketing trials eligible for outcome analysis; 154 (6.6%) had a clinical endpoint as a primary outcome, 837 (35.9%) a safety endpoint, and 1,262 (54.1%) a surrogate endpoint. Overall, 52 (2.2%) were pharmacologic studies and 26 (1.1%) were in other categories.
Location
Data regarding trial location were missing for 91 postmarketing trials (3.9%). North America (the United States and/or Canada) was the exclusive location for 1,233 of the remaining trials (54.7%), whereas 550 trials (24.4%) were conducted solely in Europe and 57 in both Europe and North America (2.5%). Supporting Information Figure S4 presents data regarding the number of patients to be enrolled in postmarketing trials by their geographical location, for each drug. It shows several inequalities, with some drugs such as panitumumab or ofatumumab almost never tested in locations 
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other than North America and Europe, and others such as sorafenib more frequently recruiting patients from nonoccidental areas.
Supplemental indications
All drugs, except nelarabine, had approvals for supplemental indications by the FDA during the study period; five were modified indications (i.e., within the cancer of the original indication) and four were new indications (approval for another cancer). Details are in Table 2 and in the Additional Supporting Information.
Trial publication
Analysis of subsequent publications according to the first method (cross-check between ClinicalTrials.gov and MED-LINE) revealed 504 publications corresponding to 393 different NCTs. After excluding articles published <18 months after the trial start date (n 5 12), NCTs with missing data regarding start date (n 5 10) and published before the trial start date (n 5 2), we selected the first published report if more than one article was found per trial. Thus, we had a sample of 379 publications from an original sample of 2,321 post-marketing trials. Publication rate at 5 years was 10.9% [95% confidence interval (CI) 9.5-12.3%]. When applying the same method but with only post-marketing trials launched before December 31, 2010, to allow for a greater mean follow-up for subsequent publication, the publication rate was 12.1% (95% CI 10.5-13.8%) at 5 years and 26.1% (95% CI 23.5-28.8%) at 10 years. Applying exactly the same process with the "trials-tracker" tool led to more conservative estimates, with an overall publication rate of 4.0% (95% CI, 3.1-4.9%) at 5 years. When selecting only post-marketing trials launched before December 31, 2010, the publication rate was 4.5% (95% CI, 3.5-5.6%) at 5 years and 12.3% (95% CI, 10.3-14.3%) at 10 years. When studying publication rate by the main sponsor with the two methods, we found a significant difference between post-marketing trials for which a drug manufacturer was the main sponsor and others, with industry-sponsored trials consistently more published than others. According to the first method, publication rates for industry versus other sponsors at 5 years and 10 years were 17.9% (95% CI 14.2-21.7%) versus 10.1% (95% CI 8.3-11.8%) and 34.9% (95% CI 29.7-40.2%) versus 22.9% (95% CI 19.8-29.5%; p < 0.0001). The "trials-tracker" method showed rates of 7.8% (95% CI, 5.2-10.4%) versus 3.3% (95% CI, 2.3-4.4%) and 19.1% (95% CI, 14.7-23.6%) versus 9.7% (95% CI, 7.6-11.7%; p < 0.0001). Figure 4 and Supporting Information Figure S5 show Kaplan-Meier curves for cumulative publications over time by the two methods, with a distinction between postmarketing trials whose main sponsor was a drug manufacturer versus others.
Discussion
Our study characterized nearly 10 years of post-marketing research for all novel anticancer agents approved by both the FDA and EMA between 2005 and 2010. We found substantial variation in number of post-marketing trials per drug and in total population size to be recruited for each drug in their post-marketing life. As well, >60% of all analyzed postmarketing trials were launched for a cancer different from that indicated in the initial drug label and some cancers were more studied than others. Finally, only 6.6% of postmarketing trials had a clinical endpoint as a primary outcome, and the publication rate of performed research was low, with poorer rates for non-industry-sponsored trials.
Our study has several strengths. It is the first to systematically examine post-marketing trials for anticancer agents over a nearly 10-year period. Our process for selecting postmarketing trials was rigorous. Recent literature on oncologic innovations is often focused regarding scope 18 or topic. 19, 20 Second, and also in contrast to previous work, we chose to study novel drugs that had been approved by both major regulators so as to obtain a more consensual drug sample. This choice is particularly relevant because further analysis of the current study was global and not just US-centered. Third, off-label use in oncology has extensively been studied and 
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described, 21-23 but we chose a slightly different approach, to be more aligned with routine care. Labels are stringently phrased by regulators 24 and off-label use then occurs as soon as a patient's condition is not strictly similar to the one depicted in the Summary of Product Characteristics. Therefore, we performed a manual review of each post-marketing trial included in our sample to determine, based on clinical judgment, whether each trial involved a substantially different cancer than that described in the initial label. This approach is thought to be more clinically relevant than mere analyses based on off-label prescribing.
Our findings have important implications for postmarketing research in oncology. We observed a very heterogeneous and liberal landscape among trials. Some drugs were more studied than were others from a purely quantitative point of view, and populations to be recruited also differed among products. >60% of all post-marketing trials involved a cancer type different from the one described in the primary label. This rate of "off-condition" trials is far more than the average value we previously found for all novel drugs approved within the same time period (Zeitoun JD, 2016, submitted). This finding might not be surprising because many cancers share the same development mechanisms 14, 25 and hence, many anticancer agents are effective or even approved for several types of tumors. Beyond the issues linked to medical relevancy, commercial interests might also influence the extensive post-marketing testing of anticancer agents because cancer has become a highly profitable market for most manufacturers.
We found hematologic malignancies and kidney cancer highly prevalent among oncologic approvals during the study period (i.e., 2005-2010), representing 10 of 13 initial regulatory indications for the whole sample. Therefore, not unsurprisingly, those two areas were also the leading conditions studied in post-marketing trials, although less prevalent in proportion, with leukemia, myeloma and kidney cancer representing one third of all post-marketing trials. In addition, post-marketing research in oncology was highly concentrated in North America and Europe. Globalization of clinical research has been described 26 and sometimes criticized, 27 but our data seem to contradict the simplistic view of emerging markets representing a preferred target for performing clinical trials. Although we have no explanation for our findings, we do not believe that they can be linked to the peculiarity of oncology because they are in line with our recent report regarding all novel drugs (Zeitoun, 2017, submitted). However, this geographic concentration raises questions regarding access to clinical trials by populations living in emerging countries and affected by cancer. We also studied the primary outcomes selected by investigators and the output of post-marketing research in terms of supplemental indications and publication. Only 6.6% of postmarketing trials had a clinical endpoint as a primary outcome. Some authors have recently shown poor correlation of surrogate oncology endpoints with overall survival, 18 but our findings raise concern about the uncommon use of this clinical endpoint as a primary outcome in post-marketing trials. Also, most drugs were associated with a label change or even a supplemental indication in a cancer other than the one originally approved over the study period. Perhaps more interestingly, we found a very low publication rate for postmarketing trials, with two methods yielding different but low results. In any case, our underreporting finding is consistent with previous publications 28, 29 even if our measures seem to be even lower than in previous research. This situation is still problematic because post-marketing trials are a main source of evidence for clinical decision making in oncology and the availability of novel data is paramount for that purpose. Of note, as compared with previous findings, 30 we found a significantly higher publication rate with both methods for post-marketing trials for which the main sponsor was industry. Our study has several limitations. First, we identified clinical trials via ClinicalTrials.gov and our study is therefore subject to registration bias. However, ClinicalTrials.gov is currently the registry of reference for clinical studies worldwide, and improved registration compliance was recently reported. 31 Extracting trials from the registry seems to be a more exhaustive approach than measuring publications because of inconsistent publication from conducted trials. 30, 32 Second, the methods we used to define and select postmarketing trials can be challenged. Actually, many clinical trials performed by industry are started after the regulatory submission yet before drug approval. We are unaware of a standard definition of post-marketing trials in the literature, even though these trials are a topic of high interest for all stakeholders. We chose to exclude preapproval trials embedded in the regulatory review and to further exclude trials whose start date was at least 1 year or more before the earliest regulatory submission. Even though other choices could have been made, this approach is rational with respect to drug development patterns. Preapproval trials were not likely mistakenly included in our sample and conversely, postmarketing trials were not likely missed. Also, some postmarketing trials are launched following regulatory commitments, but we did not identify them among our sample. Finally, our sample includes only 10 drugs, which limits the generalizability of our findings. Several factors likely explain this small number of anticancer agents. First, we chose to include drugs that had been approved by both the FDA and EMA, thereby excluding those authorized by only one of the two regulators. We chose to study drugs likely to be of greatest interest to clinicians worldwide. Second, the study period is known to be associated with a decline in therapeutic innovation, whereas the last 5 years has seen an increase in drug output, particularly in oncology. An updated version of our study might exhibit different findings, yet our work benefits from sufficient follow-up to analyze post-marketing research. Third, much of the variation we observed may be linked to the drugs being approved during a substantial time period (6 years). Consequently, follow-ups differ among drugs, thereby introducing a bias. Fourth, originally approved indications differ in prevalence and can also explain some of the variations in number and size of post-marketing trials.
In conclusion, among all novel anticancer agents approved by both the FDA and EMA between 2005 and 2010, we found great differences in subsequent post-marketing trials both in terms of the number of trials and the size of population to be enrolled. As well, about 60% of post-marketing trials were designed for a cancer different from that for which the drug was initially authorized, with a high focus on hematologic malignancies and kidney cancers. Only 6.6% of trials had a clinical endpoint as a primary outcome. Publication rate of post-marketing trials was particularly low, even after substantial follow-up, with industry-sponsored trial results significantly more often published than others. 
